undamentalytics Newsletter
Sign in

Bridgebio Pharma, Inc. (BBIO) stock

Add to watchlist

Add holding +

NASDAQ: BBIO Nasdaq Biotechnology Next results ~January 15, 2027

C+ Fundamentals grade

Bridgebio Pharma, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$34

Valuation models combined (2)

Base case. Range ~$26–$36. Weighted average of 2 models (growth cash-flow model, forward price-to-sales vs peers), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Bridgebio Pharma, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

Value diary

Our note on each quarter Bridgebio Pharma files

10-Q filed October 29: Bridgebio Pharma

Model value +30.3%

Bridgebio Pharma's revenue for the twelve months to September 2026 reached $946m, up 167.3% on a year earlier, though that pace has cooled from the 202.4% growth recorded a quarter earlier. Among the 121 biotechnology companies we cover, this growth ranks 19th. Losses have narrowed considerably: the free-cash-flow margin improved to -39.1% from -165.6% a year earlier, while the operating margin widened to -38.5% from -172.4%. Existing holders face some dilution, with the diluted share count up 2.4% on a year earlier. These shifts lift the fundamentals grade from D to C+. Accordingly, our model value climbs from $24.55 to $31.99 a share, still well below the current share price of $71.35.

Source: 10-Q filed October 29, 2026 on SEC EDGAR · Financials · Valuation

Earlier notes (1)

Where Bridgebio Pharma stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $713m, up 202.4% on a year earlier, slower than 355.2% a quarter earlier. That growth ranks 1 of 14 among the pharmaceutical preparations companies we cover. Free-cash-flow margin rose to -61.1% from -278.4% a year earlier. Operating margin widened to -69.8% from -278.4%. The diluted share count is up 2.3% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 1 of our 5 financial-health checks.

10-Q on SEC EDGAR

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 15, 2027 (estimated)

Bridgebio Pharma, Inc.'s trailing-twelve-month revenue grew 167.3% year on year, with a free-cash-flow margin of -39.1%. Where it stands out: revenue growth of 167.3% ranks 27 of 172 biotechnology companies we cover. Where it lags: long-term debt as % of assets of 121.7% ranks 78 of 78 biotechnology companies we cover.

Current signal Net margin expanding: TTM net margin reached -59.8%, up 165.5pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 167.3% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Margins widening. Operating margin is up 133.9 points on a year ago.

Things to watch

  • Growth slowing. The growth rate is 35.1 points lower than a quarter earlier.
  • Loss-making. Operating margin is -38.5%: costs exceed revenue.
  • Burning cash. Free cash flow was -39.1% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 16.1% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 2.4% in a year.
  • High sales multiple. The shares trade at 16 times revenue while operating margins remain thin.

Latest results: FY2026 Q3

Filed October 29, 2026
Earnings per share
-$0.42 against an average estimate of -$0.56: beat by 24.6%
Revenue
$353m, up 192.6% on a year earlier
Share reaction
+5.8% in the first session after the results on October 29, 2026, against -2.1% for the S&P 500
Next report
October 29, 2026; average EPS estimate -$0.40

Bridgebio Pharma's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.1%
  • 1 week+10.0%
  • 1 month+11.5%
  • This year-2.0%
  • 1 year+19.7%
  • 5 years+50.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$946M
Operating margin
-38.5%
Net margin
-59.8%
EPS (TTM, diluted)
$-2.90

Growth

Revenue growth
+167.3%
Change in growth rate
−35.1 pts
Share count change
+2.4%

Cash

Free cash flow (TTM)
-$370M
FCF margin
-39.1%
Stock pay % of revenue
16.1%

Earnings

Last results
October 29, 2026
Next results (est.)
January 15, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Results
  3. Announcement
  4. Announcement
  5. Announcement
  6. Regulatory
  7. Announcement
  8. Regulatory
  9. Regulatory
  10. Product
  11. Announcement
  12. Announcement
  13. Announcement
  14. Insider trade
  15. Agreement
  16. Results
  17. Announcement
  18. Insider trade
  19. Insider trade

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Bridgebio Pharma, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Bridgebio Pharma, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.4%: the 10-year Treasury yield (4.9%) plus a beta of 0.99 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$36 ~$16–$54 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: book value or earnings not available
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$26 ~$27–$100 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$2.8 Left out: out of range vs price (0.04x)
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$34 ~$26–$36 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Bridgebio Pharma, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2019202020212022202320242025Now
Share price$35.05$71.11$16.68$7.62$40.37$27.44$76.49$75.00
Market value$3.7bn$8.4bn$2.4bn$1.1bn$6.6bn$5.1bn$14.6bn$14.6bn
+ Net debt (− = net cash)−$268m−$262m$37m$54m$71m−$244m$1.4bn$1.1bn
Enterprise value$3.4bn$8.1bn$2.4bn$1.2bn$6.6bn$4.9bn$16.1bn$15.7bn
Multiples
Price / sales 90.8xn/m34.5x14.5xn/m23.0x29.2x15.5x
Price / earnings ————————
Price / free cash flow ————————
EV / EBITDA ————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

8 /100

Weak moat

How hard Bridgebio Pharma's competitive advantage looks for rivals to wear away, judged from 8 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -66.7% of total assets over 8 years.

  • Durability 10 / 20

    Operating margin has been a median -434.3%; its worst year was -5931.1%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 6 years, at a median -366.9% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 41.6% over five years; stock-based pay has been a median 74.8% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.62 +31% $1.0bn +107%
Next −$0.22 +91% $1.7bn +60%

Next year's EPS estimate has moved −139.5% in 90 days, across 6 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +22.3% on 90 days ago. In the last 30 days, 0 analysts raised Bridgebio Pharma, Inc.'s forecast and 8 cut it.

Consensus EPS forecast Bridgebio Pharma, Inc., last 90 days
−$3.00 −$2.00 −$1.00 $0.00 $1.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.14 Current fiscal year, 60 days ago: −$2.68 Current fiscal year, 30 days ago: −$2.58 Current fiscal year, 7 days ago: −$2.59 Current fiscal year, Now: −$2.62 −$2.62 Next fiscal year, 90 days ago: $0.57 Next fiscal year, 60 days ago: $0.15 Next fiscal year, 30 days ago: $0.03 Next fiscal year, 7 days ago: −$0.22 Next fiscal year, Now: −$0.22 −$0.22

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.14$0.57
60 days ago −$2.68$0.15
30 days ago −$2.58$0.03
7 days ago −$2.59−$0.22
Now −$2.62−$0.22

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 −$0.56 −$0.42 +24.6%
Jun 2026 −$0.58 −$0.78 −33.9%
Mar 2026 −$0.62 −$0.84 −36.2%
Dec 2025 −$0.62 −$0.94 −50.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, October 29, 2026

No numeric guidance in Bridgebio Pharma, Inc.'s latest earnings release (filed October 29, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

23 analysts, Oct 2026
Buy2087%
Hold313%
Sell00%

Monthly trend

  1. Oct 2026515323
  2. Sep 2026514322
  3. Aug 2026514322
  4. Jul 2026614222

Counts of recommendations published by analysts covering Bridgebio Pharma, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
11.4%
of tradable shares
Days to cover
6.5
at average volume
Short interest, 1 month
−7%
to October 15, 2026
Held by institutions
100%
of shares
Held by insiders
3.9%
of shares
Employees
999
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +19.7%

$62.64 on October 31, 2025 to $75.00

ThenNowEffect
Revenue (last 12 months) $236m $713m +202.4%
P/S multiple 50.4x 20.4x −59.5%
Share count 190m 194m −2.2%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

Last 3 years +160.1%

$28.83 on November 3, 2023 to $75.00

ThenNowEffect
Revenue (last 12 months) $6m $713m +12465.1%
P/S multiple n/m 20.4x −97.4%
Share count 153m 194m −21.3%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
BBIO−77%−54%+430%−32%+179%−2%
Industry peers (median)−35%−57%−18%−28%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
BBIO33%33%58%42%83%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
BBIO−84%−70%−31%−45%−20%−30%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since June 27, 2019: 93% from February 8, 2021 to May 11, 2022. Getting back needed a 1289% gain, reached on December 3, 2025, 1302 days after the low.

Price behaviour

52-week range
$61.37 – $90.17
From 52-week high
−16.8%
vs 50-day average
+6.9%
vs 200-day average
+3.1%
Volatility (1 year)
44%
Beta vs S&P 500
0.87

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±4.7%
After a week
4 up, 7 down
typical move ±6.4%
After a month
6 up, 5 down
typical move ±6.9%
Results releasedNext dayS&P 500 next day5 days21 days
October 29, 2026 +5.8% −2.1% — —
August 10, 2026 −0.9% −0.3% −5.4% −9.9%
May 7, 2026 −1.0% +0.5% +2.3% −1.1%
February 24, 2026 −2.0% +1.6% −5.0% +5.4%
January 12, 2026 +2.4% 0.0% −0.1% −5.1%
October 29, 2025 −1.8% −1.1% −2.9% +11.6%
August 5, 2025 −6.2% +0.3% +2.8% +8.5%
April 29, 2025 +6.9% +0.7% +2.9% −7.0%
February 20, 2025 +1.5% −2.1% −5.6% −4.2%
January 13, 2025 +22.4% +0.3% +24.1% +9.9%
November 12, 2024 −5.1% −0.3% −13.7% +5.9%
August 1, 2024 +0.9% −3.3% −5.7% +7.3%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Bridgebio Pharma, Inc. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Bridgebio Pharma, Inc.
$0 $500M $1B FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $9.3M Revenue (TTM), FY24 Q1: $218.6M Revenue (TTM), FY24 Q2: $219.1M Revenue (TTM), FY24 Q3: $217.8M Revenue (TTM), FY24 Q4: $221.9M Revenue (TTM), FY25 Q1: $127.4M Revenue (TTM), FY25 Q2: $235.8M Revenue (TTM), FY25 Q3: $353.8M Revenue (TTM), FY25 Q4: $502.1M Revenue (TTM), FY26 Q1: $580M Revenue (TTM), FY26 Q2: $713.1M Revenue (TTM), FY26 Q3: $945.5M $945.5M

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $9.3M
FY24 Q1 $218.6M
FY24 Q2 $219.1M
FY24 Q3 $217.8M
FY24 Q4 $221.9M
FY25 Q1 $127.4M
FY25 Q2 $235.8M
FY25 Q3 $353.8M
FY25 Q4 $502.1M
FY26 Q1 $580M
FY26 Q2 $713.1M
FY26 Q3 $945.5M
Revenue growth, TTM YoY Bridgebio Pharma, Inc.
-1000% 0% 1000% 2000% 3000% 4000% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: -88.0% Revenue growth, TTM YoY, FY24 Q1: 181.0% Revenue growth, TTM YoY, FY24 Q2: 3761.2% Revenue growth, TTM YoY, FY24 Q3: 2209.8% Revenue growth, TTM YoY, FY24 Q4: 2285.3% Revenue growth, TTM YoY, FY25 Q1: -41.7% Revenue growth, TTM YoY, FY25 Q2: 7.6% Revenue growth, TTM YoY, FY25 Q3: 62.5% Revenue growth, TTM YoY, FY25 Q4: 126.3% Revenue growth, TTM YoY, FY26 Q1: 355.2% Revenue growth, TTM YoY, FY26 Q2: 202.4% Revenue growth, TTM YoY, FY26 Q3: 167.3% 167.3%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 -88.0%
FY24 Q1 181.0%
FY24 Q2 3761.2%
FY24 Q3 2209.8%
FY24 Q4 2285.3%
FY25 Q1 -41.7%
FY25 Q2 7.6%
FY25 Q3 62.5%
FY25 Q4 126.3%
FY26 Q1 355.2%
FY26 Q2 202.4%
FY26 Q3 167.3%
Operating margin (TTM) Bridgebio Pharma, Inc.
-8000% -6000% -4000% -2000% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: -6528.8% Operating margin (TTM), FY24 Q1: -220.0% Operating margin (TTM), FY24 Q2: -232.9% Operating margin (TTM), FY24 Q3: -250.0% Operating margin (TTM), FY24 Q4: -267.2% Operating margin (TTM), FY25 Q1: -547.6% Operating margin (TTM), FY25 Q2: -278.4% Operating margin (TTM), FY25 Q3: -172.4% Operating margin (TTM), FY25 Q4: -104.2% Operating margin (TTM), FY26 Q1: -90.5% Operating margin (TTM), FY26 Q2: -69.8% Operating margin (TTM), FY26 Q3: -38.5% -38.5%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -6528.8%
FY24 Q1 -220.0%
FY24 Q2 -232.9%
FY24 Q3 -250.0%
FY24 Q4 -267.2%
FY25 Q1 -547.6%
FY25 Q2 -278.4%
FY25 Q3 -172.4%
FY25 Q4 -104.2%
FY26 Q1 -90.5%
FY26 Q2 -69.8%
FY26 Q3 -38.5%
FCF margin (TTM) Bridgebio Pharma, Inc.
-6000% -4000% -2000% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: -5686.6% FCF margin (TTM), FY24 Q1: -276.7% FCF margin (TTM), FY24 Q2: -190.1% FCF margin (TTM), FY24 Q3: -207.4% FCF margin (TTM), FY24 Q4: -235.1% FCF margin (TTM), FY25 Q1: -392.9% FCF margin (TTM), FY25 Q2: -278.4% FCF margin (TTM), FY25 Q3: -165.6% FCF margin (TTM), FY25 Q4: -89.0% FCF margin (TTM), FY26 Q1: -76.8% FCF margin (TTM), FY26 Q2: -61.1% FCF margin (TTM), FY26 Q3: -39.1% -39.1%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -5686.6%
FY24 Q1 -276.7%
FY24 Q2 -190.1%
FY24 Q3 -207.4%
FY24 Q4 -235.1%
FY25 Q1 -392.9%
FY25 Q2 -278.4%
FY25 Q3 -165.6%
FY25 Q4 -89.0%
FY26 Q1 -76.8%
FY26 Q2 -61.1%
FY26 Q3 -39.1%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 41 8 70 78 9 222 502 946
Gross profit — — 67 74 7 218 481 892
EBITDA −265 −473 −571 −505 −601 −587 −518 −359
Operating income −266 −474 −577 −512 −607 −593 −523 −364
Net income −261 −449 −563 −481 −643 −536 −725 −566
Diluted EPS −$2.48 −$3.80 −$3.90 −$3.26 −$3.95 −$2.88 −$3.78 −$2.90
Growth (year on year)
Revenue — −79.7% +745.1% +11.4% −88.0% +>999% +126.3% +167.3%
Margins
Gross margin — — 95.5% 95.6% 73.7% 98.3% 95.8% 94.3%
EBITDA margin −654.3% <−999% −818.7% −650.9% <−999% −264.5% −103.2% −38.0%
Operating margin −656.4% <−999% −827.1% −659.6% <−999% −267.2% −104.2% −38.5%
Net margin −642.5% <−999% −806.9% −619.7% <−999% −241.4% −144.4% −59.8%
Free-cash-flow margin −631.7% <−999% −733.2% −546.5% <−999% −235.1% −89.0% −39.1%
Cash flow
Cash from operations −254 −400 −498 −419 −528 −521 −446 −369
Capital spending 3 8 13 5 1 1 1 1
Free cash flow −256 −407 −511 −424 −529 −522 −447 −370
Stock-based pay 21 58 100 92 109 96 133 152
Free cash flow after stock pay −278 −466 −611 −516 −638 −617 −580 −522
Balance sheet
Cash 364 356 394 377 376 681 570 1,533
Total debt 95 94 431 431 446 437 2,007 2,630
Net debt (negative = net cash) −268 −262 37 54 71 −244 1,437 1,097
Diluted shares 105m 118m 144m 147m 163m 186m 192m 195m
Returned to shareholders
Dividends 1 — — — — — — —
Buybacks — 75 200 0 0 0 48 253
Total returned 1 75 200 0 0 0 48 253

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 5 checks passed · September 30, 2026
What it owns · $2.2bn
Short-term assets $2.0bnLonger-term assets $117m
What it owes, and who funded it · $3.8bn
Short-term liabilities $977mLonger-term liabilities $2.8bnShareholders' equity $-1.7bn
  • Short-term assets cover short-term liabilities $2.0bn of assets due within a year against $977m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $2.0bn short-term assets against $2.8bn of longer-dated liabilities.
  • More cash than debt $1.5bn of cash against $2.6bn of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$369m of operating cash flow against $2.6bn of debt.
  • Operating profit covers interest at least five times over Operating income of −$364m against $51m of interest.

From Bridgebio Pharma, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q3 TTM
Buybacks (TTM)
$253M
Buybacks, last 3 fiscal years
$48.3M
Diluted share count
+2.4%
year over year
Total shareholder yield
1.7%
dividends 0.0% + buybacks 1.7% of market value
R&D spending
56.7%
of revenue
Sales & admin spending
75.0%
of revenue
Days sales outstanding
145 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated BBIO KNSA BCRX IONS LEGN ASND Median
Revenue, last 12 months $946m $946m $941m $874m $1.0bn $814m $56m
Revenue growth, last 12 months 167.3% 58.2% 68.7% −7.4% 64.0% 106.9% 12.6%
Revenue growth, 3-year average 364.6% 56.1% 45.3% 11.5% — — 13.7%
Revenue growth, latest quarter 192.6% 58.1% 33.6% −40.7% — — 10.2%
Gross margin 94.3% 90.2% 97.8% 98.2% 61.4% 86.8% 82.9%
Operating margin −38.5% 13.8% −33.3% −68.0% −13.3% −18.9% −189.4%
Operating margin, 3-year average −153.6% 4.4% −13.1% −47.0% — <−999% −363.5%
Net margin −59.8% 11.6% −40.9% −64.7% −28.8% −31.7% −169.8%
Cash from operations / revenue −39.0% 21.0% 40.0% −56.8% −9.7% 7.5% −168.0%
Free-cash-flow margin −39.1% 20.8% 39.7% −64.2% −12.5% 7.5% −162.4%
Free-cash-flow margin, 3-year average −137.4% 13.6% 6.7% −46.3% — <−999% −310.0%
Stock pay / revenue 16.1% 4.8% 7.8% 18.7% — 16.1% 20.0%
Change in share count 2.4% 8.5% 11.4% −2.8% 0.8% 4.7% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 167.3% 12.6% 27 of 172
Change in growth rate Growth -35.1pp -0.1pp 136 of 172
Gross margin Profitability 94.3% 82.4% 14 of 75
Operating margin Profitability -38.5% -189.4% 60 of 175
Net margin Profitability -59.8% -157.3% 67 of 180
Free-cash-flow margin Cash generation -39.1% -145.4% 61 of 176
Stock pay as % of revenue Cash generation 16.1% 19.2% 80 of 179
Long-term debt as % of assets Balance sheet 121.7% 20.6% 78 of 78
Change in share count Balance sheet 2.4% 7.9% 50 of 156
Days sales outstanding Balance sheet 145 days 75 days 83 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $362M 72.2% ▲ 12464.8%
Licenses and services $128M 25.6% ▼ 41.4%
Royalty $11.4M 2.3% ▲ 6637.3%

From Bridgebio Pharma, Inc.'s 10-K filed February 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$14.4B
Institutions reporting
471
Shares held vs prior quarter
▼ 0.2%
Positions opened / closed
76 / 67

Top buyers and sellers, Q2 2026: 248 institutions bought and 230 sold ; the biggest buyer was Wellington Management Group LLP (+2.8M shares) and the biggest seller Blackrock, Inc (−3.9M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Jupiter Topco LLC $1.1B 14.1M 7.3% —
Kohlberg Kravis Roberts & Co. L.P. $988M 13.3M 6.9% 0.0%
Farallon Capital Management, L.L.C. $800M 10.7M 5.6% ▲ 14.7%
Blackrock, Inc. $766M 10.3M 5.3% ▼ 27.6%
Viking Global Investors LP $741M 9.9M 5.1% ▼ 16.0%
Vanguard Capital Management LLC $588M 7.9M 4.1% ▲ 1.8%
Vanguard Portfolio Management LLC $570M 7.7M 4.0% ▼ 5.2%
Wellington Management Group LLP $395M 5.3M 2.7% ▲ 113.7%
Two Sigma Investments, LP $352M 4.7M 2.4% ▲ 51.3%
Aisling Capital Management LP $342M 4.6M 2.4% ▼ 9.8%
State Street Corp $330M 4.4M 2.3% ▼ 10.1%
Citadel Advisors LLC $280M 3.8M 1.9% ▲ 18.5%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Bridgebio Pharma, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $101M 143 trades by 9 insiders · 88% under pre-set plans
Net ▼ $101M net selling
Insider Date Trade Shares Price Value
Kumar Neil Chief Executive Officer September 17, 2026 Sell pre-set plan 8,721 $69.01 $601,836
Kumar Neil Chief Executive Officer September 17, 2026 Sell pre-set plan 1,279 $69.57 $88,980
Kumar Neil Chief Executive Officer August 19, 2026 Sell pre-set plan 8,100 $83.86 $679,266
Kumar Neil Chief Executive Officer August 19, 2026 Sell pre-set plan 1,800 $84.69 $152,442
Kumar Neil Chief Executive Officer August 19, 2026 Sell pre-set plan 100 $85.65 $8,565
Kumar Neil Chief Executive Officer August 18, 2026 Sell pre-set plan 1,199 $83.77 $100,440
Kumar Neil Chief Executive Officer August 18, 2026 Sell pre-set plan 17,279 $82.21 $1.4M
Kumar Neil Chief Executive Officer August 18, 2026 Sell pre-set plan 1,900 $81.15 $154,185
Kumar Neil Chief Executive Officer August 18, 2026 Sell pre-set plan 14,602 $82.99 $1.2M
Apuli Maricel Chief Accounting Officer July 30, 2026 Sell pre-set plan 2,000 $80.06 $160,120
Cook Jennifer E. Director July 9, 2026 Sell pre-set plan 112,422 $90.00 $10.1M
Cook Jennifer E. Director July 9, 2026 Sell pre-set plan 36,167 $84.00 $3M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 8 trades and filings

In the last 12 months, 1 member of Congress disclosed 5 purchases and 1 sale of Bridgebio Pharma, Inc. shares.

  • Gilbert Ray Cisneros, Jr.(D-CA 31):Sale (partial), $1,001 - $15,000, traded September 29, 2026, filed October 12, 2026
  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $1,001 - $15,000, traded May 11, 2026, filed June 8, 2026
  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $1,001 - $15,000, traded April 29, 2026, filed May 8, 2026

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around January 15, 2027 estimated from the company's past filing pattern, not announced

  • October 29, 2026
  • August 10, 2026
  • May 7, 2026
  • February 24, 2026
  • January 12, 2026
  • October 29, 2025

Recent SEC filings

Data status

When each part of this page on Bridgebio Pharma, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Bridgebio Pharma, Inc. in brief

What does Bridgebio Pharma, Inc. do?
Bridgebio Pharma, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Bridgebio Pharma, Inc.'s stock ticker?
Bridgebio Pharma, Inc. trades under the ticker BBIO on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Bridgebio Pharma, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Bridgebio Pharma, Inc. reported revenue of $946M, 167.3% higher than a year earlier, according to its SEC filings.
What is Bridgebio Pharma, Inc.'s free cash flow?
Bridgebio Pharma, Inc.'s free-cash-flow margin is -39.1% of revenue over the trailing twelve months, ranking 61 of the 176 biotechnology companies we cover.
Who are Bridgebio Pharma, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Jupiter Topco LLC, Kohlberg Kravis Roberts & Co. L.P. and Farallon Capital Management, L.L.C. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Bridgebio Pharma, Inc. buying back stock, and does it pay a dividend?
Bridgebio Pharma, Inc. spent $253M on share repurchases over the trailing twelve months, and its diluted share count still rose 2.4% over the year.
What is Bridgebio Pharma, Inc.'s market cap?
On November 2, 2026, Bridgebio Pharma, Inc.'s market capitalisation was about $14.6B and net debt of $1.1B. Market figures come from third-party market data and may be delayed.
Who are Bridgebio Pharma, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Bridgebio Pharma, Inc. are Kiniksa Pharmaceuticals International, plc, Biocryst Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, Legend Biotech Corp and Ascendis Pharma A/s. The side-by-side comparison below sets their revenue, margins and growth against Bridgebio Pharma, Inc.'s.
Are insiders buying or selling Bridgebio Pharma, Inc. stock?
Over the last 12 months, Bridgebio Pharma, Inc.'s directors and officers reported 0 open-market purchases and 143 sales on Form 4. The insider trading page charts every trade.
When is Bridgebio Pharma, Inc.'s next earnings date?
Around January 15, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Bridgebio Pharma, Inc. announces its own schedule.